Health-related Quality of Life Associated with Daytime and Nocturnal Hypoglycaemic Events: a Time Trade-off Survey in Five Countries
Overview
Authors
Affiliations
Background: Hypoglycaemic events, particularly nocturnal, affect health-related quality of life (HRQoL) via acute symptoms, altered behaviour and fear of future events. We examined the respective disutility associated with a single event of daytime, nocturnal, severe and non-severe hypoglycaemia.
Methods: Representative samples were taken from Canada, Germany, Sweden, the United States and the United Kingdom. Individuals completed an internet-based questionnaire designed to quantify the HRQoL associated with different diabetes- and/or hypoglycaemia-related health states. HRQoL was measured on a utility scale: 1 (perfect health) to 0 (death) using the time trade-off method. Three populations were studied: 8286 respondents from the general population; 551 people with type 1 diabetes; and 1603 with type 2 diabetes. Respondents traded life expectancy for improved health states and evaluated the health states of well-controlled diabetes and diabetes with non-severe/severe and daytime/nocturnal hypoglycaemic events.
Results: In the general population, non-severe nocturnal hypoglycaemic events were associated with a 0.007 disutility compared with 0.004 for non-severe daytime episodes, equivalent to a significant 63% increase in negative impact. Severe daytime and nocturnal events were associated with a 0.057 and a 0.062 disutility, respectively, which were not significantly different.
Conclusions: This study applies an established health economic methodology to derive disutilities associated with hypoglycaemia stratified by onset time and severity using a large multinational population. It reveals substantial individual and cumulative detrimental effects of hypoglycaemic events - particularly nocturnal - on HRQoL, reinforcing the clinical imperative of avoiding hypoglycaemia.
The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.
Elnaggar M, Mansinho J, Malkin S, Whitaker J, Hunt B, Glah D Diabetes Ther. 2025; .
PMID: 39969755 DOI: 10.1007/s13300-025-01691-1.
Arietti P, Boye K, Guidi M, Rachman J, Federici M, Raiola R J Diabetes Metab Disord. 2025; 24(1):58.
PMID: 39886102 PMC: 11780239. DOI: 10.1007/s40200-024-01553-w.
Sakane N, Matsuhisa M, Kuroda A, Miura J, Hirota Y, Kato K Diabetol Int. 2025; 16(1):78-85.
PMID: 39877450 PMC: 11769919. DOI: 10.1007/s13340-024-00762-1.
Kirsch S, Butler G, de Fries Jensen L, Okkels A, Yssing C, Hakan-Bloch J Patient Relat Outcome Meas. 2025; 16():9-21.
PMID: 39811679 PMC: 11731022. DOI: 10.2147/PROM.S479705.
Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M Health Technol Assess. 2024; 28(80):1-190.
PMID: 39673446 PMC: 11664472. DOI: 10.3310/JYPL3536.